{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T02:38:36Z","timestamp":1789785516022,"version":"4.0.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"CAPES Foundation","award":["Brasilia\/DF 70040-020"],"award-info":[{"award-number":["Brasilia\/DF 70040-020"]}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["TRR 130 project 12"],"award-info":[{"award-number":["TRR 130 project 12"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014841","name":"MEDAC","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100014841","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s13075-017-1306-0","type":"journal-article","created":{"date-parts":[[2017,5,18]],"date-time":"2017-05-18T15:56:58Z","timestamp":1495123018000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":108,"title":["B cell repopulation kinetics after rituximab treatment in ANCA-associated vasculitides compared to rheumatoid arthritis, and connective tissue diseases: a longitudinal observational study on 120 patients"],"prefix":"10.1186","volume":"19","author":[{"given":"Jens","family":"Thiel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Rizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Engesser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann-Kathrin","family":"Dufner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Troilo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Lorenzetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard E.","family":"Voll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils","family":"Venhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,5,18]]},"reference":[{"issue":"8","key":"1306_CR1","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1002\/art.22019","volume":"54","author":"P Roll","year":"2006","unstructured":"Roll P, Palanichamy A, Kneitz C, Dorner T, Tony H-P. Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum. 2006;54(8):2377\u201386.","journal-title":"Arthritis Rheum"},{"key":"1306_CR2","doi-asserted-by":"crossref","unstructured":"Popa C, Leandro MJ, Cambridge G, Edwards JCW. Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs Rheumatology. 2007;46(4):626\u201330.","DOI":"10.1093\/rheumatology\/kel393"},{"issue":"3","key":"1306_CR3","doi-asserted-by":"crossref","first-page":"558","DOI":"10.3899\/jrheum.090856","volume":"37","author":"RF Vollenhoven van","year":"2010","unstructured":"van Vollenhoven RF, Emery P, Bingham CO, Keystone EC, Fleischmann R, Furst DE, et al. Long-term safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheumatol. 2010;37(3):558\u201367.","journal-title":"J Rheumatol"},{"issue":"2","key":"1306_CR4","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1164\/rccm.200507-1144OC","volume":"173","author":"KA Keogh","year":"2006","unstructured":"Keogh KA, Ytterberg SR, Fervenza FC, Carlson KA, Schroeder DR, Specks U. Rituximab for refractory Wegener's granulomatosis. Am J Respir Crit Care Med. 2006;173(2):180\u20137.","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"1306_CR5","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1136\/ard.2011.153601","volume":"71","author":"JU Holle","year":"2012","unstructured":"Holle JU, Dubrau C, Herlyn K, Heller M, Ambrosch P, Noelle B, et al. Rituximab for refractory granulomatosis with polyangiitis (Wegener's granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestations. Ann Rheum Dis. 2012;71(3):327\u201333.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"1306_CR6","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1136\/ard.2007.083162","volume":"67","author":"D Albert","year":"2008","unstructured":"Albert D, Dunham J, Khan S, Stansberry J, Kolasinski S, Tsai D, et al. Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus. Ann Rheum Dis. 2008;67(12):1724\u201331.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"1306_CR7","first-page":"386","volume":"372","author":"C Pagnoux","year":"2015","unstructured":"Pagnoux C, Guillevin L. French Vasculitis Study G, investigators M. Rituximab or azathioprine maintenance in ANCA-associated vasculitis. N Engl J Med. 2015;372(4):386\u20137.","journal-title":"N Engl J Med"},{"issue":"5","key":"1306_CR8","doi-asserted-by":"crossref","first-page":"e37626","DOI":"10.1371\/journal.pone.0037626","volume":"7","author":"N Venhoff","year":"2012","unstructured":"Venhoff N, Effelsberg NM, Salzer U, Warnatz K, Peter HH, Lebrecht D, et al. Impact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitides. PLoS One. 2012;7(5):e37626.","journal-title":"PLoS One"},{"key":"1306_CR9","doi-asserted-by":"crossref","unstructured":"Yates M, Watts RA, Bajema IM, Cid MC, Crestani B, Hauser T, et al. EULAR\/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016;23:2016;75(9):1583\u201394.","DOI":"10.1136\/annrheumdis-2016-209133"},{"issue":"6","key":"1306_CR10","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3109\/08916934.2014.914174","volume":"47","author":"N Venhoff","year":"2014","unstructured":"Venhoff N, Niessen L, Kreuzaler M, Rolink AG, H\u00e4ssler F, Rizzi M, et al. Reconstitution of the peripheral B lymphocyte compartment in patients with ANCA-associated vasculitides treated with rituximab for relapsing or refractory disease. Autoimmunity. 2014;47(6):401\u20138.","journal-title":"Autoimmunity"},{"issue":"8","key":"1306_CR11","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1002\/art.1780330806","volume":"33","author":"AT Masi","year":"1990","unstructured":"Masi AT, Hunder GG, Lie JT, Michel BA, Bloch DA, Arend WP, et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum. 1990;33(8):1094\u2013100.","journal-title":"Arthritis Rheum"},{"key":"1306_CR12","doi-asserted-by":"crossref","unstructured":"Leavitt RY, Fauci AS, Bloch DA, Michel BA, Hunder GG, Arend WP, et al. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. 1990; 33(8):1101\u20137.","DOI":"10.1002\/art.1780330807"},{"issue":"7","key":"1306_CR13","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1002\/art.24637","volume":"60","author":"RB Jones","year":"2009","unstructured":"Jones RB, Ferraro AJ, Chaudhry AN, Brogan P, Salama AD, Smith KGC, et al. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody\u2013associated vasculitis. Arthritis Rheum. 2009;60(7):2156\u201368.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"1306_CR14","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/ar3797","volume":"14","author":"RM Smith","year":"2012","unstructured":"Smith RM, Jones RB, Jayne DR. Progress in treatment of ANCA-associated vasculitis. Arthritis Res Ther. 2012;14(2):210.","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"1306_CR15","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1002\/art.34583","volume":"64","author":"RM Smith","year":"2012","unstructured":"Smith RM, Jones RB, Guerry MJ, Laurino S, Catapano F, Chaudhry A, et al. Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2012;64(11):3760\u20139.","journal-title":"Arthritis Rheum"},{"issue":"9","key":"1306_CR16","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1002\/art.22046","volume":"54","author":"KG Smith","year":"2006","unstructured":"Smith KG, Jones RB, Burns SM, Jayne DR. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment. Arthritis Rheum. 2006;54(9):2970\u201382.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"1306_CR17","doi-asserted-by":"crossref","first-page":"409","DOI":"10.2169\/internalmedicine.46.6156","volume":"46","author":"N Tamura","year":"2007","unstructured":"Tamura N, Matsudaira R, Hirashima M, Ikeda M, Tajima M, Nawata M, et al. Two cases of refractory Wegener's granulomatosis successfully treated with rituximab. Intern Med. 2007;46(7):409\u201314.","journal-title":"Intern Med"},{"issue":"9","key":"1306_CR18","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1177\/0091270007305297","volume":"47","author":"F Breedveld","year":"2007","unstructured":"Breedveld F, Agarwal S, Yin M, Ren S, Li NF, Shaw TM, et al. Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response. J Clin Pharmacol. 2007;47(9):1119\u201328.","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"1306_CR19","doi-asserted-by":"publisher","first-page":"e0155218","DOI":"10.1371\/journal.pone.0155218","volume":"11","author":"M V\u00f6gelin","year":"2016","unstructured":"V\u00f6gelin M, Biedermann L, Frei P, Vavricka SR, Scharl S, Zeitz J, et al. The impact of azazioprine-associated lymphopenia on the onset of opportunistic infections in patients with inflammatory bowel disease. PLoS One. 2016;11(5):e0155218. doi: 10.1371\/journal.pone.0155218 .","journal-title":"PLoS One"},{"issue":"2","key":"1306_CR20","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/MEG.0b013e32834233a2","volume":"23","author":"A Al Rifai","year":"2011","unstructured":"Al Rifai A, Prasad N, Shuttleworth E, McBurney H, Pushpakom S, Robinson A, et al. Natural history of azathioprine-associated lymphopenia in inflammatory bowel disease patients: a prospective observational study. Eur J Gastroenterol Hepatol. 2011;23(2):153\u20138.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"8","key":"1306_CR21","doi-asserted-by":"crossref","first-page":"891","DOI":"10.2217\/pgs.15.29","volume":"16","author":"RL Roberts","year":"2015","unstructured":"Roberts RL, Barclay ML. Update on thiopurine pharmacogenetics in inflammatory bowel disease. Pharmacogenomics. 2015;16(8):891\u2013903.","journal-title":"Pharmacogenomics"}],"container-title":["Arthritis Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-017-1306-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T22:26:41Z","timestamp":1589754401000},"score":1,"resource":{"primary":{"URL":"http:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-017-1306-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,18]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["1306"],"URL":"https:\/\/doi.org\/10.1186\/s13075-017-1306-0","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,18]]},"article-number":"101"}}